MétaCan
Menu
Back to cohort

Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31.

2014· article· en· W2603167024 on OpenAlexaff
Diep Ho, Jessica Huang, Judy‐Anne W. Chapman, Kim Leitzel, Suhail M. Ali, Lois E. Shepherd, Wendy R. Parulekar, Catherine Ellis, Rocco J. Crescenzo, Liting Zhu, Shakeel Virk, Dora Nomikos, Samuel Aparício, Karen A. Gelmon, Walter P. Carney, Allan Lipton

Bibliographic record

VenueJournal of Clinical Oncology · 2014
Typearticle
Languageen
FieldMedicine
TopicHER2/EGFR in Cancer Research
Canadian institutionsBC Cancer AgencyQueen's University
Fundersnot available
KeywordsMedicineLapatinibTrastuzumabInternal medicineTaxaneMetastatic breast cancerOncologyBreast cancerMultivariate analysisUnivariate analysisCancer

Abstract

fetched live from OpenAlex

617 Background: The lapatinib-taxane combination led to shorter PFS than trastuzumab-taxane in HER2+ metastatic breast cancer. We investigated the prognostic and predictive effects of pretreatment serum HER2, CA IX, and TIMP-1. Methods: MA.31 accrued 652 patients; 537 (82%) were centrally-confirmed HER2+. Biomarkers were categorized for univariate and multivariate predictive investigations with a median cut-point, ULN cut-points (15 ng/ml for HER2; 506 pg/ml for CAIX; 454 pg/ml for TIMP-1), and custom cut-points (30 and 100 ng/ml for HER2). Stratified step-wise forward Cox multivariate analysis used continuous and categorical biomarkers for PFS in the ITT and central HER2+ populations; central HER2+ biomarker results are shown. Results: Serum was banked for 472 (72%) of 652 patients. Higher serum HER2 (>median; >15; >30; or >100 ng/ml; p=0.05-0.002); higher CAIX (>median; >506 pg/ml; p=0.02; p=0.001); and higher TIMP-1 (>median; >454 pg/ml; p=0.001; p=0.02) had worse univariate PFS. In multivariate analysis, higher continuous TIMP-1 was associated with significantly worse PFS: HR=1.001 (95% CI=1.000-1.002; p=0.004). Continuous serum HER2 and CAIX were not significantly associated with PFS. HER2 of 15 ng/ml or higher had shorter PFS (p=0.02); higher categorical CAIX had worse PFS (p=0.01-0.08). The interaction terms of HER2, CAIX, and TIMP-1 with treatment were not significant. Multivariate PFS categorical serum results (Table). Conclusions: Higher levels of serum TIMP-1, CAIX, and HER2 were significant prognostic biomarkers of shorter PFS. No serum biomarker was predictive of differential response to lapatinib vs. trastuzumab. Evaluation of TIMP-1 and CAIX targeted therapy in addition to HER2 targeted therapy is warranted in patients with elevated serum levels of these biomarkers. p-value HR Lower CI Higher CI LTax vs TTax 0.001 1.58 1.20 2.06 Adjuvant anthracyclines 0.011 1.58 1.11 2.25 Adjuvant other therapy 0.043 3.88 1.04 14.41 EGFR (% stain) 0.012 1.01 1.001 1.01 Serum HER2 (>15 vs <15 ng/ml) 0.023 1.51 1.06 2.15 Serum CAIX (>506 vs <506 pg/ml) 0.005 1.54 1.14 2.08 *DH and JH contributed equally.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.081
GPT teacher head0.482
Teacher spread0.402 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicHER2/EGFR in Cancer ResearchFrench-language works237,207